Compare Merck & Co., Inc. (MRK) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Payoneer Global Inc — how do they compare? Merck & Co., Inc. trades at $142.58 (market cap $351.28B), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: Merck & Co., Inc. is far larger — about 144.6× Payoneer Global Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Payoneer Global Inc for 61 Days on average.
| MRK | PAYO | |
|---|---|---|
Market Cap | $351.28B | $2.43B |
Volume | 7,969,665 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $156.43 | $7.18 |
52-Week Low | $82.49 | $4.27 |
Typical Hold Time | 98 Days | 61 Days |
Enterprise Value | $398.04B | $2.17B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Payoneer (PAYO) trades at $7.16, up 0.14% on the day, with a bullish technical signal from moving averages and a mixed earnings history including a Q2 2026 miss. Revenue grew to $821.16M in 2025, but net income declined to $73.19M, compressing margins. The company renewed its partnership with Etsy through 2029 and faces ongoing legal scrutiny regarding its proposed acquisition by Nuvei.
The outlook is cautious; while analyst consensus is 60% buy-rated and cash flow trends are positive, risks include earnings volatility, acquisition uncertainty, and competitive pressures. Investors should weigh strong institutional interest against execution challenges and margin pressures for medium-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
